REG - Futura Medical PLC - Trading Update

Futura MedicalAnnouncement

04/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260204:nRSD6027Ra&default-theme=true

RNS Number : 6027R  Futura Medical PLC  04 February 2026

4 February 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Trading Update

 

 

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and
that specialises in the development and global commercialisation of innovative
and clinically proven sexual health products, is pleased to provide an
unaudited trading update for the year ended 31 December 2025 (FY25).

 

The Company now expects to deliver FY25 revenue of £1.7 million, ahead of
previously guided management expectations*. Additionally, net cash at year end
was £3.4 million following the successful £2.75 million fundraise in
November 2025. As previously announced, under the Company's existing agreement
with Haleon and subject to the granting of a U.S. patent for Eroxon, the
Company expects to trigger a milestone payment from Haleon of US$2.5 million
during H1 2026; in addition, the Company expects to receive a tax credit
refund for FY2025 of approximately £0.3 million.

 

The Company's existing cash resources including the net proceeds of the
fundraise in November 2025, combined with the expected tax credit refund for
the 2025 financial year, the US patent milestone payment from Haleon and
proceeds from ongoing sales of Eroxon, are expected to provide the Company
with a cash runway to December 2026, which is in line with prior statements.

 

As previously announced, the Board is undertaking a strategic review of the
business and its operations which is expected to conclude in Q1 2026. The
outcomes of the review will be published in the Company's Full Year Results
which are expected to be released mid-April 2026.

 

*On 19(th) September 2025, the Company disclosed that it expected to deliver
revenue between £1.3 million and £1.4 million for FY25

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014
as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.

 

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date. Multiple distribution partnerships are in place for
Eroxon, across major consumer markets.

 

The WSD4000 is a prototype product designed for the symptoms of impaired
sexual response and function in women. There is currently no regulatory
approved OTC treatment available for impaired sexual response and function in
women. WSD4000 has the potential to be an effective, breakthrough treatment
for the common symptoms associated with impaired sexual response and function,
such as lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTAKNBNKBKBFBK



            Copyright 2019 Regulatory News Service, all rights reserved